SCHEMBL27166293

SCHEMBL27166293

CCCCCCCCCCCCCCCCCCCCOCC(O)COC(=O)CCCCCCCCCCCCCCC

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.69
KDM4E B2RXH2 1/20 0.69
DUSP3 P51452 1/20 0.69
MEN1 O00255 1/20 0.69
KMT2A Q03164 1/20 0.69
ENPP2 Q13822 4/20 0.64
LPAR1 Q92633 3/20 0.64
LPAR5 Q9H1C0 2/20 0.64
LPAR6 P43657 1/20 0.64
LPAR4 Q99677 1/20 0.64
LPAR2 Q9HBW0 1/20 0.64
LPAR3 Q9UBY5 1/20 0.64
MAPT P10636 1/20 0.63
DGKA P23743 2/20 0.58
USP2 O75604 1/20 0.57
ALDH1A1 P00352 1/20 0.57
TRPV1 Q8NER1 1/20 0.56
HTT P42858 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19241181 1.00 LMNA (0.69) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL25229650 1.00 LMNA (0.69) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL10477783 1.00 LMNA (0.69) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL23042348 1.00 LMNA (0.69) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL16236223 0.98 LMNA (0.66) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL15096661 0.97 LMNA (0.69) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL12554333 0.97 LMNA (0.69) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL12554987 0.97 LMNA (0.69) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL19941706 0.95 LMNA (0.71) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL6368636 0.94 KDM4E (0.59) LMNAKDM4EDUSP3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12214080-B2 Micronized lipids MCAL THERAPEUTICS INC. (US) 2025-02-04 US claimed
US-12214079-B2 Micronized lipids MCAL THERAPEUTICS INC. (US) 2025-02-04 US claimed
EP-4333794-A1 MICRONIZED LIPIDS MCAL Therapeutics Inc. (US) 2024-03-13 EP claimed
CN-117580560-A Micronised lipid MCAL治疗公司 2024-02-20 CN claimed
US-20220362154-A1 MICRONIZED LIPIDS MCAL THERAPEUTICS INC. 2022-11-17 US claimed
US-20220362155-A1 MICRONIZED LIPIDS MCAL THERAPEUTICS INC. 2022-11-17 US claimed
US-20250221933-A1 MICRONIZED LIPIDS MCAL THERAPEUTICS INC. 2025-07-10 US disclosed
US-20250221934-A1 MICRONIZED LIPIDS MCAL THERAPEUTICS INC. 2025-07-10 US disclosed
US-12214079-B2 Micronized lipids MCAL THERAPEUTICS INC. (US) 2025-02-04 US disclosed
US-12214080-B2 Micronized lipids MCAL THERAPEUTICS INC. (US) 2025-02-04 US disclosed
CN-117580560-A Micronised lipid MCAL治疗公司 2024-02-20 CN disclosed
US-20220362154-A1 MICRONIZED LIPIDS MCAL THERAPEUTICS INC. 2022-11-17 US disclosed
US-20220362155-A1 MICRONIZED LIPIDS MCAL THERAPEUTICS INC. 2022-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220362155-A1 MICRONIZED LIPIDS SGMS1, SGMS2, MGLL LMNA 3981/4885KDM4E 3924/4885DUSP3 618/4885
US-20250221933-A1 MICRONIZED LIPIDS SGMS1, SGMS2, MGLL LMNA 3981/4885KDM4E 3924/4885DUSP3 618/4885
US-20220362154-A1 MICRONIZED LIPIDS SGMS1, SGMS2, MGLL LMNA 3981/4885KDM4E 3924/4885DUSP3 618/4885
US-20250221934-A1 MICRONIZED LIPIDS SGMS1, SGMS2, MGLL LMNA 3981/4885KDM4E 3924/4885DUSP3 618/4885
US-12214079-B2 Micronized lipids SGMS1, SGMS2, MGLL LMNA 3981/4885KDM4E 3924/4885DUSP3 618/4885
US-12214080-B2 Micronized lipids SGMS1, SGMS2, MGLL LMNA 3981/4885KDM4E 3924/4885DUSP3 618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.